Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens

被引:51
作者
Ardeshna, KM [1 ]
Kakouros, N
Qian, W
Powell, MG
Saini, N
D'Sa, S
Mackinnon, S
Hoskin, PJ
Goldstone, AH
Linch, DC
机构
[1] Mt Vernon Canc Ctr, Northwood HA6 2RN, Middx, England
[2] UCL Hosp, Dept Haematol, London, England
[3] MRC, Clin Trials Unit, London, England
关键词
salvage chemotherapy; non-Hodgkin's lymphoma; Hodgkin's Lymphoma; autologous stem cell transplant; inadequate partial response;
D O I
10.1111/j.1365-2141.2005.05603.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to determine the outcome of patients with relapsed or refractory lymphoma who have an inadequate response to first- line salvage therapy (1 degrees ST) and who subsequently receive a second-line salvage regimen (2 degrees ST) with the intention of ultimately proceeding to high-dose therapy. The outcome of 57 patients [ Hodgkin's Lymphoma 17, histologically-aggressive non-Hodgkin's Lymphoma (NHL) 26, histologically-indolent NHL 14] who received more than one modality of conventional- dose salvage therapy was analysed. Sixteen patients had a partial response (PR) to 1 degrees ST, but subsequently received 2 degrees ST because the PR was judged to be inadequate ( iPR) because of persisting disease bulk or marrow infiltration. Of these 16 patients, 10 (63%) continued to respond to 2 degrees ST. Of the 15 patients who had stable disease following 1 degrees ST, 5 (33%) responded to 2 degrees ST. Only one of the 24 (4%) with progressive disease (PD) following 1 degrees ST, responded to 2 degrees ST. 25 of the 57 patients ultimately underwent stem cell transplantation. The 2-year progression-free survival (PFS) and the 3-year overall survival ( OS) for all patients was 24% and 31%, respectively. Long-term survival was highly dependent on response to 1 degrees ST (P = 0.0001); in patients with PD following 1 degrees ST, the PFS and OS at 3 years was only 4%. This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored.
引用
收藏
页码:363 / 372
页数:10
相关论文
共 33 条
  • [1] High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
    Bierman, PJ
    Vose, JM
    Anderson, JR
    Bishop, MR
    Kessinger, A
    Armitage, JO
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 445 - 450
  • [2] CABANILLAS F, 1982, BLOOD, V60, P693
  • [3] CERVANTES F, 1995, BONE MARROW TRANSPL, V16, P387
  • [4] CHAU ICD, 2003, BLOOD, V102, P1448
  • [5] 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Chen, CI
    Roitman, D
    Tsang, R
    Stewart, AK
    Keating, A
    Crump, M
    [J]. BONE MARROW TRANSPLANTATION, 2002, 30 (12) : 885 - 891
  • [6] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [7] MINI-BEAM FOLLOWED BY BEAM AND ABMT FOR VERY POOR RISK HODGKINS-DISEASE
    CHOPRA, R
    LINCH, DC
    MCMILLAN, AK
    BLAIR, S
    PATTERSON, KG
    MOIR, D
    RICHARDS, JDM
    CERVI, P
    KINSEY, S
    GOLDSTONE, AH
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (02) : 197 - 202
  • [8] CHOPRA R, 1993, BLOOD, V81, P1137
  • [9] MINI-BEAM AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY HODGKINS-DISEASE BEFORE INTENSIVE THERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    COLWILL, R
    CRUMP, M
    COUTURE, F
    DANISH, R
    STEWART, AK
    SUTTON, DMC
    SCOTT, JG
    SUTCLIFFE, SB
    BRANDWEIN, JM
    KEATING, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) : 396 - 402
  • [10] HIGH-DOSE ETOPOSIDE AND MELPHALAN, AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ADVANCED HODGKINS-DISEASE - IMPORTANCE OF DISEASE STATUS AT TRANSPLANT
    CRUMP, M
    SMITH, AM
    BRANDWEIN, J
    COUTURE, F
    SHERRET, H
    SUTTON, DMC
    SCOTT, JG
    MCCRAE, J
    MURRAY, C
    PANTALONY, D
    SUTCLIFFE, SB
    KEATING, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) : 704 - 711